Patent Family Confirmations
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
5 January 2016
Recce Patent Family Confirmation
Australian early-stage pharmaceutical company, Recce Ltd (ASX: RCE), confirms (as required) the
following statements:
1. P.R China Patent - Allowed Status
P.R. China Application 200880124515.5 has been allowed and fees paid by the Company such that
grant is anticipated to be completed shortly. In view of P.R. China Application 200880124515.5 being
allowed, a decision is now pending on whether or not to continue with P.R. China Application
201410136135.0 (Divisional).
2. Provisional Applications of Family 2 - Submitted
Further, Recce confirms the provisional applications to maintain the priority benefit of the applications
the subject of Family 2 “Copolymer and Method for Treatment of Parenteral Infection” were submitted
by the due date of 18 November 2015.
For further information please visit www.recce.com.au or contact:
Investor Relations
Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800
Media Communication
Karen Oswald – karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353
About Recce Ltd
Recce, led by Dr Graham Melrose, is a world-leader in synthetic-polymer antibiotics. RECCE
antibiotics have been synthesised by an extremely simple and economic method.
RECCE antibiotics have shown in laboratory tests that they have continued activity against bacteria
including superbugs, even after repeated use.
Recce is positioned to achieve milestones in both manufacturing of RECCE antibiotics, and the preclinical regulatory requirements - that should drive significant value for the Company.
Share your feedback
Discover